Oncology | Drugs in Discovery | Pipeline Prospector

CytomX Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

CytomX Therapeutics and Astellas Announce Strategic Collaboration

Lead Product(s): T-cell bispecific antibodies

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Astellas

Deal Size: $1,600.0 million Upfront Cash: $80.0 million

Deal Type: Collaboration March 23, 2020

Details:

Under this collaboration, the parties will utilize CytomX’s Probody® therapeutic technology platform, as well as its proprietary bispecific formats and CD3 modules.

Karolinska Institutet

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Sweden

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Zelluna Immunotherapy collaborates with Karolinska Institutet

Lead Product(s): TCR based Natural Killer cell

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Zelluna Immunotherapy

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 12, 2020

Details:

The collaboration will support a multi-year research program with Dr. Evren Alici, that aims to develop next generation TCR guided NK cells.

Xilio Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing

Lead Product(s): XTX201

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Takeda Ventures

Deal Size: $100.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing March 02, 2020

Details:

Proceeds from the financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 and XTX101 through Investigational New Drug enabling studies and into Phase 1 clinical trials.

Riptide Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Riptide Bioscience Announces Discovery of Novel Immune Checkpoint

Lead Product(s): RP-182,Gemcitabine

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 13, 2020

Details:

RP-182, administered in combination with gemcitabine, produced the best results ever shown in NCI’s KRAS-p16 pancreatic cancer model.

KSQ Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

KSQ Therapeutics Announces Discovery of Gene Targets to PD-1

Lead Product(s): Undisclosed

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 09, 2020

Details:

Data demonstrate potential to increase efficacy of TIL adoptive cell therapy in preclinical models.

Stony Brook University

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Stony Brook University gets $4.2 million NCI grant

Lead Product(s): ART26.12

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: National Cancer Institute

Deal Size: $4.2 million Upfront Cash: Undisclosed

Deal Type: Funding February 03, 2020

Details:

FABP5 platform is under Artelo Biosciences ' exclusive license. NCI support provides further validation of next-generation target for cancer therapeutics.

Effector Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types.

Lead Product(s): Undisclosed

Therapeutic Area: Oncology

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Pfizer

Deal Size: $507.0 million Upfront Cash: $15.0 million

Deal Type: Collaboration January 09, 2020

Details:

This license and collaboration agreement is to develop small-molecule inhibitors of eukaryotic initiation factor 4E, a key oncogenic driver located downstream from both the RAS and PI3K pathways.

Find

Find Novel Oncology Drugs in Discovery

Discovery

A collaboration with SCORR Marketing

Product Type

Companies

CytomX Therapeutics

CytomX Therapeutics and Astellas Announce Strategic Collaboration

Karolinska Institutet

Zelluna Immunotherapy collaborates with Karolinska Institutet

Xilio Therapeutics

Akrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing

Riptide Bioscience

Riptide Bioscience Announces Discovery of Novel Immune Checkpoint

KSQ Therapeutics

KSQ Therapeutics Announces Discovery of Gene Targets to PD-1

Stony Brook University

Stony Brook University gets $4.2 million NCI grant

Effector Therapeutics

eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-in-Class Inhibitors of eIF4E to Treat Multiple Cancer Types.